Judy William V
Integr Med (Encinitas). 2022 Nov;21(5):30-35.
The science of the metabolism of CoQ10 before and after its absorption into the blood is well known. Almost nothing is known about the absorption of CoQ10 into the lymph.
The study intended to measure and compare the single-dose absorption of three CoQ10 product formulations-crystal-free ubiquinone, crystalline ubiquinol, and a dry-powder ubiquinone-into the abdominal lymph duct as compared to their absorption into the blood circulation.
The researcher designed an animal study.
The animals were six large dogs (>50 Kg).
By gastric gavage, the dogs were given a 100-mg dose of either crystal-free ubiquinone (Q-Best), crystalline ubiquinol (Qunol), or dry-powder ubiquinone, and lymph and venous samples (5 ml) were collected.
The primary end-point measurements for three CoQ10 product types were the concentration (Cmax), time of Cmax (Tmax), and total CoQ10 absorbed into the lymph and that transported to the blood.
Coenzyme Q10 (CoQ10) crystals were found in the dry powder and crystalline ubiquinol formulations. No crystals were found in the crystal-free formulation. Crystals from both the crystalline and dry-powder formulations were found in the small intestine's chyme. After ingestion of a 100-mg dose of CoQ10 formulation, the group mean absorption into the lymph peaked in 2 hours for all three formulations, and the peak appearance (Cmax) in the blood occurred at 6 hours. The absorption was significantly ( ≤ .001) greater for the crystal-free formulation compared to that of the crystalline and dry-powder formulations measured in the lymph and plasma.
These data show that the crystal-free formulation's absorption is superior to that found for the other two formulations. These results show that CoQ10 crystals are the causative factor for the poor absorption of CoQ10. The delayed appearance in the blood is due to the slow lymph flow delivering CoQ10 to the blood. The absorption of CoQ10 may not be as poor as described in the literature.
辅酶Q10被吸收进入血液前后的代谢科学已为人熟知。而关于辅酶Q10被吸收进入淋巴的情况几乎一无所知。
本研究旨在测量并比较三种辅酶Q10产品剂型——无定形泛醌、结晶型泛醇和干粉状泛醌——单剂量进入腹部淋巴管的吸收情况,并与它们进入血液循环的吸收情况进行比较。
研究者设计了一项动物研究。
实验动物为6只大型犬(体重>50千克)。
通过胃管给犬灌胃100毫克剂量的无定形泛醌(Q-Best)、结晶型泛醇(Qunol)或干粉状泛醌,然后采集淋巴和静脉样本(5毫升)。
三种辅酶Q10产品类型的主要终点测量指标为浓度(Cmax)、达到Cmax的时间(Tmax)以及吸收进入淋巴和转运至血液的辅酶Q10总量。
在干粉状和结晶型泛醇剂型中发现了辅酶Q10(CoQ10)晶体。在无定形剂型中未发现晶体。在小肠食糜中发现了来自结晶型和干粉状剂型的晶体。摄入100毫克剂量的辅酶Q10剂型后,所有三种剂型进入淋巴的平均吸收量在2小时达到峰值,而血液中的峰值出现时间(Cmax)为6小时。与在淋巴和血浆中测得的结晶型和干粉状剂型相比,无定形剂型的吸收量显著更高(≤0.001)。
这些数据表明,无定形剂型的吸收优于其他两种剂型。这些结果表明,辅酶Q10晶体是辅酶Q10吸收不良的致病因素。血液中出现延迟是由于淋巴流动缓慢将辅酶Q10输送到血液中。辅酶Q10的吸收可能并不像文献中描述的那么差。